You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Moodys
Harvard Business School
McKinsey
AstraZeneca

Last Updated: July 15, 2020

DrugPatentWatch Database Preview

LITHOBID Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Lithobid patents expire, and when can generic versions of Lithobid launch?

Lithobid is a drug marketed by Ani Pharms Inc and is included in one NDA.

The generic ingredient in LITHOBID is lithium carbonate. There are fifteen drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the lithium carbonate profile page.

US ANDA Litigation and Generic Entry Outlook for Lithobid

A generic version of LITHOBID was approved as lithium carbonate by HIKMA on January 29th, 1982.

  Start Trial

Drug patent expirations by year for LITHOBID
Drug Prices for LITHOBID

See drug prices for LITHOBID

Recent Clinical Trials for LITHOBID

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
William V. Bobo, M.D.Phase 2
Patient-Centered Outcomes Research InstituteN/A
Montana State UniversityN/A

See all LITHOBID clinical trials

Pharmacology for LITHOBID
Drug ClassMood Stabilizer

US Patents and Regulatory Information for LITHOBID

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ani Pharms Inc LITHOBID lithium carbonate TABLET, EXTENDED RELEASE;ORAL 018027-001 Approved Prior to Jan 1, 1982 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Moodys
Harvard Business School
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.